SDLRituximab Biosimilar (Truxima) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
MSHLRituximab (MabThera) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
For cancer treatment in line with HSA registered indication(s).
MSHLRituximab (MabThera) Solution For Subcutaneous Injection 1,400 mg/11.7 mL
1) Rituximab (subcutaneous) in combination with cyclophosphamide, doxorubicin, vincristine and pred...
MSHLRituximab (MabThera) Solution For Subcutaneous Injection 1,400 mg/11.7 mL
1) Rituximab (subcutaneous) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), for the treatment of CD20+ diffuse large B-cell non-Hodgkin lymphoma.
2) Rituximab (subcutaneous) in combination with cyclophosphamide, vincristine, prednisone (CVP), for the treatment of previously untreated patients with stage III–IV follicular lymphoma.
3) Rituximab (subcutaneous) for maintenance treatment of patients with follicular lymphoma who have responded to induction therapy.
MSHLRituximab biosimilar (Truxima) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
For cancer treatment.
MSHLRituximab (MabThera) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
1) Ibrutinib in combination with rituximab for previously untreated chronic lymphocytic leukaemia (...
MSHLRituximab (MabThera) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
1) Ibrutinib in combination with rituximab for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
2) Ibrutinib in combination with rituximab, for the treatment of Waldenstrom’s Macroglobulinaemia.
MSHLRituximab (MabThera) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
Venetoclax in combination with rituximab (non-subsidised brand) for patients with chronic lymphocyt...
MSHLRituximab (MabThera) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
Venetoclax in combination with rituximab (non-subsidised brand) for patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. Maximum treatment duration of rituximab is 6 cycles and venetoclax is 24 months.
MSHLRituximab (Truxima) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
1) Ibrutinib in combination with rituximab for previously untreated chronic lymphocytic leukaemia (...
MSHLRituximab (Truxima) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
1) Ibrutinib in combination with rituximab for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
2) Ibrutinib in combination with rituximab, for the treatment of Waldenstrom’s Macroglobulinaemia.
MSHLRituximab biosimilar (Truxima) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
Venetoclax in combination with rituximab biosimilar (subsidised brand) for patients with chronic ly...
MSHLRituximab biosimilar (Truxima) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
Venetoclax in combination with rituximab biosimilar (subsidised brand) for patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. Maximum treatment duration of rituximab is 6 cycles and venetoclax is 24 months.
MSHLRituximab (Rixathon) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
1) Ibrutinib in combination with rituximab for previously untreated chronic lymphocytic leukaemia (...
MSHLRituximab (Rixathon) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
1) Ibrutinib in combination with rituximab for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
2) Ibrutinib in combination with rituximab, for the treatment of Waldenstrom’s Macroglobulinaemia.
MSHLRituximab biosimilar (Rixathon) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
For cancer treatment.
MSHLRituximab (Rixathon) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
Venetoclax in combination with rituximab (non-subsidised brand) for patients with chronic lymphocyt...
MSHLRituximab (Rixathon) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
Venetoclax in combination with rituximab (non-subsidised brand) for patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. Maximum treatment duration of rituximab is 6 cycles and venetoclax is 24 months.